Kiniksa Pharmaceuticals, Ltd. (KNSA) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
KNSA Revenue Growth
Revenue Breakdown (FY 2025)
KNSA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
KNSA Revenue Analysis (2016–2025)
As of May 8, 2026, Kiniksa Pharmaceuticals, Ltd. (KNSA) generated trailing twelve-month (TTM) revenue of $754.0 million, reflecting explosive growth of +55.5% year-over-year. The most recent quarter (Q1 2026) recorded $214.3 million in revenue, up 6.0% sequentially.
Looking at the longer-term picture, KNSA's historical revenue data shows a 3-year CAGR of +45.5%. The company achieved its highest annual revenue of $677.6 million in 2025, representing a new all-time high.
Revenue diversification analysis shows KNSA's business is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARDX (+18.2% YoY), and RCUS (+67.4% YoY), KNSA has underperformed the peer group in terms of revenue growth. Compare KNSA vs ARDX →
KNSA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| KNSACurrent | $754M | +55.5% | - | 11.4% | |
 ARDX | $407M | +18.2% | +121.9% | -10.1% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% |
KNSA Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $677.6M | +60.1% | $370.1M | 54.6% | $77.2M | 11.4% |
| 2024 | $423.2M | +56.6% | $362.3M | 85.6% | $-45,616,000 | -10.8% |
| 2023 | $270.3M | +22.7% | $213.7M | 79.1% | $-25,196,000 | -9.3% |
| 2022 | $220.2M | +471.2% | $197.3M | 89.6% | $9.8M | 4.4% |
| 2021 | $38.5M | - | $29.4M | 76.4% | $-156,636,000 | -406.4% |
| 2020 | $0 | - | $-3,805,000 | - | $-157,363,000 | - |
| 2019 | $0 | - | $-3,279,000 | - | $-169,963,000 | - |
| 2018 | $0 | - | $-286,000 | - | $-108,160,000 | - |
| 2017 | $0 | - | $-28,000 | - | $-65,400,000 | - |
| 2016 | $0 | - | $-22,000 | - | $-24,002,000 | - |
See KNSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KNSA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KNSA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKNSA — Frequently Asked Questions
Quick answers to the most common questions about buying KNSA stock.
Is KNSA's revenue growth accelerating or slowing?
KNSA revenue is accelerating at +55.5% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $754M. Growth momentum has increased versus prior periods.
What is KNSA's long-term revenue growth rate?
Kiniksa Pharmaceuticals, Ltd.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +55.5% is above this long-term average.
How is KNSA's revenue distributed by segment?
KNSA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.